Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Efp4.3
Efpeglenatid – Forschung
Überwiegend Mechanismus / Beobachtung
24 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Efpeglenatid sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2019–2026 mit einer typischen Studiengröße von 4,076 Teilnehmenden.
Basierend auf 24 Studien · 8 Meta-Analysen · 11 RCTs · 430,627 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Glycemic controlDosisabhängige HbA1c-Senkungen über das gesamte Programm; gepoolte Metaanalyse HbA1c -0,84 % gegenüber Placebo · Wochen bis Monate
Überwiegend Mechanismus / Beobachtung23 Studien
Cardiovascular & renal outcomesAMPLITUDE-O senkte den primären MACE-Komposit-Endpunkt um 27 % gegenüber Placebo (HR 0,73) bei Hochrisiko-Typ-2-Diabetes · Über ~1,8 Jahre
Überwiegend Mechanismus / Beobachtung11 Studien
Weight & body compositionBei Adipositas ohne Diabetes placebobereinigter Gewichtsverlust von ~6,3-7,2 kg über 20 Wochen (Phase 2) · Monate (titriert)
Überwiegend Mechanismus / Beobachtung10 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung6 Studien
Aktives Forschungsgebiet
20 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
Einfach gesagt: Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis]; CRD420251032222).
Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. · Journal of the American College of Cardiology (2025)
We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls.
GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders.
Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.
Einfach gesagt: Further research is warranted to elucidate the molecular pathways underlying its anti-metastatic properties and to explore its role in preventive oncology.
Hsu CW, Zeng BS, Liang CS, Zeng BY, Hung CM, Stubbs B, Chen YW, Lei WT, Chen JJ, Chen PH, Su KP, Chen TY, Tseng PT. · International journal of molecular sciences (2025)
This NMA of 207,606 participants from 67 RCTs revealed that only efpeglenatide demonstrated a statistically significant reduction in metastatic cancer events compared to controls (odds ratio = 0.26, 95% confidence intervals = 0.09 to 0.70, p = 0.010, number needed to treat = 188.4).
Efpeglenatide's efficacy was not confined to specific cancer types.
Safety profiles were comparable across all treatments.
Einfach gesagt: In conclusion, efpeglenatide is a promising treatment for T2DM and obesity, offering effective glycemic control, weight reduction, cardiovascular and renal benefits, a favorable safety profile, and convenient dosing.
Narayan N, Vadde T, Sandesara M, Divity S, Mamytova A, Tagaev T. · Cureus (2025)
The findings of these studies consistently indicate that efpeglenatide significantly reduces hemoglobin A1C (HbA1C), fasting plasma glucose (FPG), and body weight in patients with T2DM and obesity.
Most studies show a low risk of bias and enhanced reliability.
However, limitations include the need for long-term safety data and variations in study design.
Einfach gesagt: The profound biochemical and weight loss outcomes associated with incretin co-/poly-agonists are expected to translate into outstanding cardiometabolic benefits, the theme of this evidence review.
Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM. · World journal of cardiology (2025)
Other drugs of the same group in development include Orforglipron, which has a high weight loss efficacy (-15% weight reduction).
The revolutionary triple agonists at the GLP-1, GIP, and Glucagon receptors have demonstrated the highest achievable weight loss with pharmacotherapy.
Retatrutide and Efocipegtrutide belong to this novel group of drugs.
Einfach gesagt: These findings provide a structured evidence map to inform future consensus and clinical decision-making.
Rico-Fontalvo J, Daza-Arnedo R, Elbert A, Correa-Rotter R, Dina-Batlle E, Lorca-Herrera E, de Moraes TP, Sánchez-Polo V, Builes-Montaño CE. · Diabetes therapy : research, treatment and education of diabetes and related disorders (2026)
Across agents, renal benefits were partly independent of glycemic and weight effects.
Conclusion GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes.
Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents.
Einfach gesagt: Future large-scale, high-quality clinical trials are needed to validate these findings and further optimize comprehensive cardiovascular management strategies for patients.
An X, Sun W, Wen Z, Duan L, Zhang Y, Kang X, Ji H, Sun Y, Jiang L, Zhao X, Gao Q, Lian F. · Diabetes, obesity & metabolism (2025)
GLP-1RAs did not significantly increase the incidence of adverse events, but Orforglipron and Taspoglutide significantly increased the incidence of gastrointestinal adverse events compared with placebo.
Conclusion This study compared the cardiovascular benefits of different GLP-1RAs, including reductions in cardiovascular events and improvements in multiple cardiovascular risk factors.
However, due to limitations in the quantity and quality of the included studies, the conclusions should be interpreted with caution.
Einfach gesagt: Conclusion In this post hoc analysis from the AMPLITUDE-O trial, changes in LDL cholesterol together with UACR but not weight were estimated to statistically account for a modest portion of the reduction in risk of MACE with efpeglenatide.
Aims In the AMPLITUDE O trial, efpeglenatide reduced major cardiovascular events by 27% in 4076 individuals with Type 2 diabetes and established cardiovascular or kidney disease compared to placebo during a median follow-up of 1.81 years.
The hazard (95% CI) per 1-unit increase in each time-updated mediator (change from baseline or updated mean) was estimated using Cox models adjusted for the same variables as in the main AMPLITUDE-O results.
Of these, univariable analyses showed that only changes in HbA1c, LDL cholesterol, UACR and amylase accounted for 14%, 11%, 16% and 10%, respectively, of the effect of efpeglenatide on MACE.
Einfach gesagt: The beneficial effect of efpeglenatide on these outcomes is independent of FIB-4 category.
Del Prato S, Li Z, Ramasundarahettige C, Branch KRH, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N, Gerstein HC. · Cardiovascular diabetology (2024)
Results Baseline FIB-4 score was available for 4059 participants (99.6%) allowing subdivision of the population in tertiles.
During a median follow-up of 1.8 years, numerical increases in the incidence of all 3 outcomes did not change significantly across tertiles of FIB-4 score (P for trend ≥ 0.25) with negligible relationship of the score to incident outcomes (MACE HR, per 1 SD higher score, 95% CI: 1.00, 0.89-1.13).
Efpeglenatide's effect on all MACE outcomes did not vary across FIB-4 tertiles (all interaction p values ≥ 0.64).
19Systematische Übersichtn=83,215 · very large study2026
Einfach gesagt: Overall, these findings support guideline-based use of GLP-1 RAs in high-risk T2D while highlighting the need for individualized treatment selection.
Abomohsen M, Rifai M, Gadelmawla AF, Alghzawi HM, Elgendy MS, Bakr HM, Friedman A, Idries IY. · Canadian journal of diabetes (2026)
We conducted a frequentist random-effects network meta-analysis and reported risk ratios (RRs) with 95% confidence intervals (CIs).
In the 3-point major adverse CV event (MACE) network (11 trials, 11 regimens), heterogeneity and inconsistency were absent (I 2 =0%, τ 2 =0).
MACE rate was reduced with subcutaneous semaglutide (RR 0.74, 95% CI 0.58 to 0.94), efpeglenatide (0.76, 0.61 to 0.94), and albiglutide (0.79, 0.69 to 0.91); tirzepatide, oral semaglutide, liraglutide, and dulaglutide were also significantly reduced compared with placebo.
Einfach gesagt: All efpeglenatide doses ≥1 mg significantly reduced HbA1c versus placebo (placebo-adjusted least squares [LS] mean changes 0.6-1.2%, P < 0.05 for all)... masked efpeglenatide 4 mg was noninferior to open-label liraglutide.
Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, Hompesch M, Choi IY, Kang J, Stewart J, Yoon KH. · Diabetes Care (2019)
Phase-2 'EXCEED 203' 12-week randomized, double-blind, placebo-controlled dose-ranging study in early type 2 diabetes (drug-naive or on metformin), referenced to open-label liraglutide 1.8 mg (exploratory)
All efpeglenatide doses ≥1 mg lowered HbA1c by a placebo-adjusted 0.6-1.2% to a final HbA1c of 6.3-6.8%; the 4 mg dose was noninferior to liraglutide
Greater weight loss with 3 and 4 mg vs placebo (placebo-adjusted -1.4 and -2.0 kg); no neutralizing antibodies detected